omniture
Aprinoia Therapeutics Inc.

Latest News

Initiation of a Phase 2 Multicenter Study of 18F-APN-1607, a Novel Diagnostic PET Imaging Tracer for the Characterization of Tau Burden in Alzheimer's Disease

TAIPEI, Nov. 21, 2019 /PRNewswire/ -- APRINOIA Therapeutics, Inc. announced today that it has initi...

2019-11-21 23:00 542

APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research

TAIPEI, , May 23, 2019 /PRNewswire/ -- APRINOIA Therapeutics, a clinical-stage biotechnology compan...

2019-05-23 20:00 2032

APRINOIA Therapeutics Licenses Tau PET Imaging Tracer APN-1607 to Celgene

TAIPEI, , Jan. 2, 2019 /PRNewswire/ -- APRINOIA Therapeutics, a clinical-stage biotechnology compan...

2019-01-02 08:00 956

APRINOIA Therapeutics Closes US$11 Million Series B Financing to Advance Its Tau PET Imaging Tracer and Tau Therapeutic Programs for Alzheimer's Disease

TAIPEI, , Jan. 16, 2018 /PRNewswire/ -- APRINOIA Therapeutics Inc., a clinical-stage neuroscience b...

2018-01-16 14:54 760